Alzheimers Disease: Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Alzheimers Disease: Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011

Description:

This report presents a comprehensive review of autoantibodies, and pipeline vaccines and therapeutic antibodies, in Alzheimer’s disease (AD). Currently, drug treatments for AD are dominated by cholinesterase inhibitors and an NMDA receptor antagonist. – PowerPoint PPT presentation

Number of Views:134

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Alzheimers Disease: Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011


1
Aarkstore.com Alzheimers Disease
Autoantibodies, Vaccines and Therapeutic
Antibodies Pipeline, 2011
2
Summary
  • This report presents a comprehensive review of
    autoantibodies, and pipeline vaccines and
    therapeutic antibodies, in Alzheimers disease
    (AD). Currently, drug treatments for AD are
    dominated by cholinesterase inhibitors and an
    NMDA receptor antagonist. While these treatments
    give benefits to some patients, there is an
    urgent need for disease-modifying therapies. New
    drug classes are in the pipeline however,
    significant growth in this field is in the
    development of vaccines and therapeutic
    antibodies. AutoantibodiesAutoantibodies are
    antibodies that target an individuals own
    proteins. In some cases, the immune system may
    respond aberrantly to normal proteins, as seen in
    autoimmune diseases. The immune system may also
    respond to proteins that are changed (for
    example, by disease), resulting in them being
    recognised as non-self. Autoantibodies are now
    attracting significant interest in the AD field,
    with more than twenty types identified and
    studied, notably relating to Abeta. The
    presence of autoantibodies in AD patients is
    highly relevant to the current immunotherapeutic
    pipeline (vaccines and therapeutic antibodies)
    being developed to target this disease. As well
    as their diagnostic significance, autoantibodies
    may also give insights into new treatment
    strategies.

3
Table of Contents
  • Executive SummaryThe Development
    PipelineCompaniesEmerging OpportunitiesGeneral
    ConclusionsChapter 1 Background p. 151.
    Alzheimers Disease1.1 Statistics and Costs1.2
    Histopathology1.3 Amyloid Beta1.4 Tau Proteins
    and Neurofibrillary Tangles1.5 Cholinergic 1.6
    Diagnosis1.7 Cognitive Tests 1.8 Stages of
    Alzheimers Disease 1.9 Treatment of Alzheimers
    Disease 1.10 Autoantibodies1.11 Autoantibodies
    the Diagnosis of Alzheimers Disease

4
More Related Reports
  •   VEGF Inhibition Therapy-Indicating and
    Prognostic Biomarkers, 2011
  •   Biomarkers in Alzheimers Disease, 2011
  •   Alzheimers Disease Autoantibodies, Vaccines
    and Therapeutic Antibodies Pipeline, 2011
  •   Prostate Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Breast Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Alzheimers Disease Biomarkers in Cerebrospinal
    Fluid and Blood, 2011
  •   Image-Based Biomarkers in Alzheimers Disease,
    2011
  •   Lung Cancer Vaccines and Therapeutic
    Antibodies Pipeline, Strategies and Clinical

5
For More details
  • http//www.aarkstore.com/reports/Alzheimers-Diseas
    e-Autoantibodies-Vaccines-and-Therapeutic-Antibodi
    es-Pipeline-2011-146440.html
  • Vina
  • Aarkstore.com
  • Contact Marketing team
  • Mob.No.918149852585
  • Email enquiry_at_aarkstore.com
  • URL http//www.aarkstore.com/
  • XML http//www.aarkstore.com/feeds/Biopharmrepor
    ts.xml
About PowerShow.com